BD releases 2018 Sustainability Report BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2018 Sustainability Report, focusing on ...

FRANKLIN LAKES, N.J. , July 23, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today issued its 2018 Sustainability Report, focusing on management of the environmental, social and governance factors that support the company's 2020 Sustainability Goals .

BD's sustainability strategy is driven by its purpose – Advancing the world of health ™ – and focuses on four priorities that are most relevant to the business and its stakeholders:

"BD's 2020 sustainability goals reflect our commitment to the role we play in finding solutions to complex global issues in partnership with our employees, customers and stakeholders," said Vincent A. Forlenza , chairman and CEO. "We are pleased with the progress we have made toward our goals and believe there are opportunities ahead to make a real difference as we work to address global challenges such as climate change and antimicrobial resistance."

Highlights from this year's report include:

New to this year's report, BD spotlights three global challenge areas – human rights, climate change, antimicrobial resistance – and details how these topics intersect with work across the four key priorities of the company's sustainability strategy.

For more information about the company's sustainability goals, view the 2018 Sustainability Report here: https://www.bd.com/en-us/company/sustainability-at-bd .

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com .

SOURCE BD (Becton, Dickinson and Company)